GTC
FPRX

Ghost Tree Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Ghost Tree Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500,000
Closed -$8.5M – 60
2020
Q4 		$8.5M Buy
+500,000
New +$6.26M 1.9% 23
2016
Q1 		– Sell
-100,000
Closed -$4.15M – 70
2015
Q4 		$4.15M Sell
100,000
-400,000
-80% -$13.4M 1.7% 25
2015
Q3 		$7.7M Buy
500,000
+75,000
+18% +$1.61M 3.46% 3
2015
Q2 		$10.6M Buy
425,000
+325,000
+325% +$7.24M 3.42% 6
2015
Q1 		$2.28M Buy
+100,000
New +$2.52M 0.82% 51

Other funds holding FPRX

BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Rock Springs Capital Management
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alpine Associates Management
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Ghost Tree Capital's FPRX Position: Q1 2021 in Review

Ghost Tree Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 500,000 shares — an estimated $8.5M sold.

Ghost Tree Capital first reported a position in FPRX in Q1 2015 and held it in 5 quarters. The position peaked at $10.6M in Q2 2015. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Ghost Tree Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Ghost Tree Capital sold 500,000 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $8.5M.
  • Ghost Tree Capital first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 5 quarters.
  • Ghost Tree Capital's Five Prime Therapeutics, Inc. position peaked at $10.6M in Q2 2015.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Ghost Tree Capital's 13F filing for Q1 2021, filed 14 May 2021.